Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly E Dooley

Showing results (41-50 of 170) with videos related to

Pageof 17
Sort By:
The Journal of Infectious Diseases|July 19, 2012
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Kelly E Dooley, Ekwaro A Obuku, Nadza Durakovic, et al.
Antimicrobial Agents and Chemotherapy|September 13, 2021
<i>In Vitro</i> Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessusOlumide Martins, Jin Lee, Amit Kaushik, et al.
Expert Review of Clinical Pharmacology|August 15, 2017
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Omamah Alfarisi, Wael A Alghamdi, Mohammad H Al-Shaer, et al.
Pathogens (Basel, Switzerland)|January 21, 2022
Tuberculous Meningitis in Children: Reducing the Burden of Death and DisabilityJulie Huynh, Yara-Natalie Abo, Karen du Preez, et al.
Plos Neglected Tropical Diseases|January 20, 2011
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceDeepak Almeida, Paul J Converse, Zahoor Ahmad, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2013
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosisElin M Svensson, Francesca Aweeka, Jeong-Gun Park, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2022
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)Caryn M Upton, Chanel I Steele, Gary Maartens, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 4, 2020
Tenofovir alafenamide use in pregnant and lactating women living with HIVAhizechukwu C Eke, Kristina M Brooks, Rahel D Gebreyohannes, et al.
The Lancet. HIV|March 9, 2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infectionMax R O'Donnell, Nesri Padayatchi, Amrita Daftary, et al.
BMC Public Health|March 2, 2011
Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in MoroccoKelly E Dooley, Ouafae Lahlou, Iraqi Ghali, et al.
Pageof 17

Showing results (41-50 of 170) with videos related to

Sort By:
Pageof 17
The Journal of Infectious Diseases|July 19, 2012
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Kelly E Dooley, Ekwaro A Obuku, Nadza Durakovic, et al.
Antimicrobial Agents and Chemotherapy|September 13, 2021
<i>In Vitro</i> Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessusOlumide Martins, Jin Lee, Amit Kaushik, et al.
Expert Review of Clinical Pharmacology|August 15, 2017
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Omamah Alfarisi, Wael A Alghamdi, Mohammad H Al-Shaer, et al.
Pathogens (Basel, Switzerland)|January 21, 2022
Tuberculous Meningitis in Children: Reducing the Burden of Death and DisabilityJulie Huynh, Yara-Natalie Abo, Karen du Preez, et al.
Plos Neglected Tropical Diseases|January 20, 2011
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceDeepak Almeida, Paul J Converse, Zahoor Ahmad, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2013
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosisElin M Svensson, Francesca Aweeka, Jeong-Gun Park, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2022
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)Caryn M Upton, Chanel I Steele, Gary Maartens, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 4, 2020
Tenofovir alafenamide use in pregnant and lactating women living with HIVAhizechukwu C Eke, Kristina M Brooks, Rahel D Gebreyohannes, et al.
The Lancet. HIV|March 9, 2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infectionMax R O'Donnell, Nesri Padayatchi, Amrita Daftary, et al.
BMC Public Health|March 2, 2011
Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in MoroccoKelly E Dooley, Ouafae Lahlou, Iraqi Ghali, et al.
Pageof 17